in5points
BusinessMoneycontrol

Buy Piramal Pharma; target of Rs 245: ICICI Securities

in5points

  1. ICICI Securities issued a 'buy' rating on Piramal Pharma with a target price of Rs 245.

  2. The research report is dated July 31, 2026.

  3. The recommendation suggests potential upside from the current market price.

4h ago · original ↗
Buy Piramal Pharma; target of Rs 245: ICICI Securities · in5points